Exploratory Pharmacodynamic Study of Tenofovir-Based Products

HIV Clinical Trial

Official title:

Phase I Exploratory Pharmacodynamic Study of Tenofovir-Based Products

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02722343
• Other study ID #: A15-140
• Status: Completed
• Phase: Phase 1
• First received: March 9, 2016
• Last updated: September 1, 2016
• Start date: April 2016
• Est. completion date: August 2016

Study information

• Verified date: September 2016
• Source: CONRAD
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This single site study is designed to describe and measure the efficacy of oral versus vaginal dosing of TFV-based products, specifically emtricitabine/tenofovir disoproxil fumarate oral tablets (Truvada) vs tenofovir intravaginal rings (IVR).

Description:

This study will compare an investigational intravaginal ring containing tenofovir (TFV) with an FDA approved medication in tablet form called Truvada®. It will assess and compare the ability of the tablet and intravaginal ring to prevent HIV transmission (human immunodeficiency virus, the virus that causes AIDS).

The study will enroll healthy, non-pregnant, HIV negative, premenopausal women (aged 18-50, with regular menstrual cycles) who are not at risk of pregnancy.

The enrollment goal is for 20 participants to complete the study.

Participants will be assigned to use one of the study products: oral tablet or intravaginal ring. Participants will take the oral tablet each day for 14 days or wear the intravaginal ring all day and night for 14 days/nights. Blood, genital fluid samples and genital tissue samples (biopsies) will be taken at two visits. These sample collections will take place before and after use of the assigned study product. The samples will be tested to:

1. Determine the levels of drug in the blood and genital tissue samples

2. See if the samples taken from the vagina and cervix after use of study product, provides protection from HIV in the laboratory

3. Ensure that the laboratory test used to measure HIV infection in the samples performs well when used repeatedly.

In addition this study will also evaluate the returned TFV rings to see whether they were used as instructed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: August 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• General good health (by volunteer history and per investigator judgment) without any clinically significant systemic disease (including, but not limited to significant liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis or bone disease, and diabetes) and with an intact gastrointestinal tract, uterus and cervix

• Currently have regular menstrual cycles of 21-35 days by participant record

• Willing to abstain from vaginal intercourse and any other vaginal activity including use of vaginal products (tampons, spermicides, lubricants, and douches) other than study products:

• 48 hours before Visit 2 until six days after Visit 2

• 48 hours before Visit 3 until six days after Visit 4

• Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to easy genital tract sample collection

• Estimated calculated creatinine clearance (eCcr) of at least 60 mL/min

• History of Pap smears and follow-up consistent with standard clinical practice as outlined in the study manual or willing to undergo a Pap smear at Visit 1

• Protected from pregnancy by one of the following:

• sterilization of either partner

• abstinence

• same sex relationship

• condoms

• combined contraceptives (including oral, patch)

• copper IUD

• Willing and able to comply with protocol requirements including swallowing tablets

• Willing to give voluntary consent and sign an informed consent form

Exclusion Criteria:

• History of hysterectomy

• Currently pregnant or within two calendar months from the last pregnancy outcome. Note: if recently pregnant must have had at least two spontaneous menses since pregnancy outcome

• Injection of Depo-Provera in the last 10 months or use of other progestin-only based contraceptive (including hormonal IUD)

• Currently breastfeeding or planning to breastfeed during the course of the study

• History of sensitivity/allergy to any component of the study products, topical anesthetic, or to both silver nitrate and Monsel's solution

• In the last three months, diagnosed with or treated for any STI, by self report

• Positive test for Trichomonas vaginalis, Neisseria gonorrhea, Chlamydia trachomatis, HIV, or Hepatitis B surface antigen (HBsAg) Note: Women with a history of genital herpes who have been asymptomatic for at least three months may be considered for eligibility

• Chronic or acute vulvar or vaginal symptoms (pain, irritation, spotting/bleeding, discharge, etc.)

• Known bleeding disorder that could lead to prolonged or continuous bleeding with biopsy

• Systemic use in the last two weeks or anticipated use during the study of any of the following: corticosteroids, antibiotics, anticoagulants or other drugs known to prolong bleeding and/or clotting, antifungals, or antivirals (e.g., acyclovir, valacyclovir, Viread®, Atripla®, Emtriva®, or Complera®)

• Current or anticipated chronic use of NSAIDS, or Tylenol for the duration of the study

• Grade 2 or higher laboratory abnormality, per the 2014 update of the Division of AIDS, National Institute of Allergy and Infectious Disease (DAIDS) Table for Grading the Severity of Adverse Events, or clinically significant laboratory abnormality as determined by the clinician

• Abnormal finding on laboratory or physical examination or a social or medical condition in either the volunteer or which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data

• Known current drug or alcohol abuse which could impact study compliance

• Participation in any other investigational trial within the last 30 days or planned participation in any other investigational trial during the study

• History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix within the last 14 days

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

• HIV

Intervention

Drug:
• Tenofovir intravaginal ring
The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
• Truvada
The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)

Locations

Country	Name	City	State
United States	Eastern Virginia Medical School	Norfolk	Virginia

Sponsors (4)

Lead Sponsor	Collaborator
CONRAD	Agility Clinical, Inc., Eastern Virginia Medical School, University of North Carolina

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adherence markers in used IVRs	Adherence biomarkers from used IVRs returned to clinic after two weeks of use	Day 14	No
Primary	p24 antigen production in cervico-vaginal tissues infected with HIV	• Assess p24 antigen production in cervicovaginal tissues infected ex vivo with HIV-1BaL at baseline and after using Truvada tablets or tenofovir intravaginal ring	Day 14	No
Primary	Analysis of integrated DNA	Integrated viral DNA in cervicovaginal tissues infected ex vivo with HIV-1BaL at baseline and after using Truvada tablets or tenofovir intravaginal ring	Day 14	No
Primary	Anti-HIV activity in cervicovaginal fluid (CVF)	Anti-HIV activity in cervicovaginal fluid at baseline and after using Truvada tablets and tenofovir intravaginal ring	Day 14	No
Secondary	Cervicovaginal tissue, fluid and plasma concentrations of tenofovir	Concentrations after use of Truvada tablets and tenofovir intravaginal ring	Day 14	No
Secondary	Cervicovaginal tissue concentration of tenofovir diphosphate	Concentrations after use of Truvada tablets and tenofovir intravaginal ring.	Day 14	No
Secondary	Cervicovaginal tissue, fluid and plasma concentrations of emtricitabine	Concentrations after use of Truvada tablets and tenofovir intravaginal ring.	Day 14	No
Secondary	Cervicovaginal tissue concentration of emtricitabine triphosphate	Concentrations after use of Truvada tablets and tenofovir intravaginal ring.	Day 14	No
Secondary	Endogenous nucleotide concentrations in cervicovaginal tissue	Endogenous nucleotides; dATP and dCTP concentrations in cervicovaginal tissue after use of Truvada tablets and tenofovir intravaginal ring	Day 14	No